| 词条 | Dextrallorphan |
| 释义 |
| IUPAC_name = (+)-(13α,14α)-17-allylmorphinan-3-ol | image = Dextrallorphan.svg | tradename = | pregnancy_category = | legal_status = Uncontrolled | routes_of_administration = Oral | bioavailability = | metabolism = | elimination_half-life = | excretion = | CAS_number = 5822-43-5 | ATC_prefix = none | ATC_suffix = | PubChem = 5748237 | ChemSpiderID = 2339009 | C=19 | H=25 | N=1 | O=1 | molecular_weight = 283.41 g/mol | smiles = Oc1ccc3c(c1)[C@]24[C@@H]([C@H](N(CC2)C\\C=C)C3)CCCC4 }}Dextrallorphan (DXA) is an opioid derivative chemical of the morphinan class that is used in scientific research. It acts as a σ1 receptor agonist and NMDA receptor antagonist.[1][2][3][4] It has no significant affinity for the σ2, μ-opioid, or δ-opioid receptor, or for the serotonin or norepinephrine transporter.[2][5] As an NMDA receptor antagonist, in vivo, it is approximately twice as potent as dextromethorphan, and five-fold less potent than dextrorphan.[3] Uses in Scientific ResearchMasking of sigma-1 receptorDextrallorphan is often used in research to block σ1 receptor sites so that σ2 receptor sites (which have not been cloned yet) can be studied.[6][7][8] It was hypothesized that both of these sigma (σ) receptors were opioid receptors, due to their affinity for psychoactive drugs. However, it is now understood that they are non-opioid receptors that bind to certain psychoactive drugs, like dextrallorphan.[9] One example of dextrallorphan being used to mask σ1 receptor sites was seen in a study on the localization of the σ2 receptor in detergent-resistant lipid raft domains.[6] It has also been used to mask σ1 receptor sites so that σ2 receptor binding characteristics in the rat liver could be determined, by labeling σ2 receptor sites with [3H]l,3-di-o-tolylguanidine (DTG) in the presence of 1 μM dextrallorphan solution.[8] Animal StudiesDextrallorphan was used in Spraque-Dawley rats to study cerebellar Purkinje neurons electrophysical responses to the drug when it was applied iontophoretically as a sigma (σ) receptor ligand. Dextrallorphan increased the firing rate by 14%, suggesting that sigma (σ) ligands (like dextrallorphan) alter the spontaneous firing of Purkinje neurons and cause motor effects.[10] In another study, dextrallorphan, along with other opioid derivatives, was found to be a potent inhibitor of etorphine-inaccessible (EI) sites in the guinea-pig brain. Dextrallorphan was of the top three most potent opioid inhibitors of those studied, with a concentration of 67 nM required to show 50% inhibition.[1] History{{Primary sources|section|date=December 2014}}In 1955, dextrallorphan has been used to study inhibition of cholinesterase's and to look at the relationship between analgetics and acetylcholine metabolism.[11] It was found that dextrallorphan inhibits 25% of bovine erythrocyte cholinesterase at a dose of 10−3 mole/liter, which corresponds to a concentration of up to 0.2 mg/kg in dog intestine. However, at this dose the drug showed no effect on the gut tone. Dextrallorphan was classified as a potent inhibitor of the intestinal and red blood cell cholinesterase based on the concentration of the drug needed to inhibit these enzymes in the cholinesterase preparations from the animals systems utilized. Simultaneously, dextrallorphan showed no analgesia and no change in intestinal tone. With these results dextrallorphan helped proved that there is no correlation between the inhibition of cholinesterase systems and analgetic or intestinal effects.[12] In 1979, dextrallorphan was found to have a half maximal inhibitory concentration (IC50) for binding to the pituitary and brain receptor of 10,000 ± 1000 nM and 10,000 ± 1500 nM, respectively. While its stereoisomer, levallorphan, had a 10,000 times more potent dose, thus proving that binding to these receptors is stereospecific.[13] See also
References1. ^1 {{ cite journal | author = Su, T. P. | title = Evidence for Sigma Opioid Receptor: Binding of [3H]SKF-10047 to Etorphine-Inaccessible Sites in Guinea-Pig Brain | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 223 | issue = 2 | pages = 284–290 |date=Nov 1982 | pmid = 6290634 | doi = | url = http://jpet.aspetjournals.org/content/223/2/284.full.pdf | format = pdf }} {{Hallucinogens}}{{Ionotropic glutamate receptor modulators}}{{Sigma receptor modulators}}2. ^1 {{ cite journal |author1=Codd, E. E. |author2=Shank, R. P. |author3=Schupsky, J. J. |author4=Raffa, R. B. | title = Serotonin and Norepinephrine Uptake Inhibiting Activity of Centrally Acting Analgesics: Structural Determinants and Role in Antinociception | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 274 | issue = 3 | pages = 1263–1270 |date=Sep 1995 | pmid = 7562497 | doi = | url = http://jpet.aspetjournals.org/content/274/3/1263.full.pdf | format = pdf }} 3. ^1 {{ cite journal |author1=Shukla, V. K. |author2=Lemaire, S. | title = N-Methyl-D-Aspartate Antagonist Activity of Alpha- and Beta-Sulfallorphans | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 280 | issue = 1 | pages = 357–365 |date=Jan 1997 | pmid = 8996216 | doi = | url = http://jpet.aspetjournals.org/content/280/1/357.full.pdf | format = pdf }} 4. ^{{ cite journal | author = Shannon, H. E. | title = Pharmacological Evaluation of N-Allynormetazocine (SKF 10,047) on the Basis of its Discriminative Stimulus Properties in the Rat | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 225 | issue = 1 | pages = 144–152 |date=Apr 1983 | pmid = 6834266 | doi = }} 5. ^{{ cite journal |author1=He, X. S. |author2=Bowen, W. D. |author3=Lee, K. S. |author4=Williams, W. |author5=Weinberger, D. R. |author6=de Costa, B. R. | title = Synthesis and Binding Characteristics of Potential SPECT Imaging Agents for Sigma-1 and Sigma-2 Binding Sites | journal = Journal of Medicinal Chemistry | volume = 36 | issue = 5 | pages = 566–571 |date=Mar 1993 | pmid = 8496936 | doi = 10.1021/jm00057a006 | url = }} 6. ^1 {{ cite journal |author1=Gebreselassie, D. |author2=Bowen, W. D. | title = Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes | journal = European Journal of Pharmacology | volume = 493 | issue = 1-3 | pages = 19–28 |date=June 2004 | pmid = 15189760 | doi = 10.1016/j.ejphar.2004.04.005| url = http://www.sciencedirect.com/science/article/pii/S0014299904003802 | format = pdf }} 7. ^{{ cite journal |author1=Maeda, D. Y. |author2=Williams, W. |author3=Bowen, W. D. |author4=Coop, A. | title = SA sigma-1 receptor selective analogue of BD1008. a potential substitute for (+)-opioids in sigma receptor binding assays | journal = Bioorganic & Medicinal Chemistry Letters | volume = 10 | issue = 1 | pages = 17–18 |date=Jan 2000 | pmid = 10636233 | doi = 10.1016/s0960-894x(99)00590-9| url = http://www.sciencedirect.com/science/article/pii/S0960894X99005909 | format = pdf }} 8. ^1 {{ cite journal |author1=Torrence-Campbell, C. |author2=Bowen, W. D. | title = Differential solubilization of rat liver sigma-1 and sigma- 2 receptors: retention of sigma- 2 sites in particulate fractions | journal = European Journal of Pharmacology | volume = 304 | issue = 1-3 | pages = 201–210 |date=May 1996 | pmid = 8813603 | doi = 10.1016/0014-2999(96)00109-4| url = http://www.sciencedirect.com/science/article/pii/0014299996001094 | format = pdf }} 9. ^{{ cite journal |author1=Hayashi, T. |author2=Su, T. | title = The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology | journal = Current Neuropharmacology | volume = 3 | issue = 4 | pages = 267–280 |date= Oct 2005 | doi = 10.2174/157015905774322516| pmc = 2268997| pmid=18369400}} 10. ^{{ cite journal |author1=Martin, W. J. |author2=De Costa, B. R. |author3=Walker, J. M. | title = Effects of σ ligands on rat cerebellar purkinje neuron firing: An iontophoretic study | journal = Brain Research Bulletin | volume = 35 | issue = 4 | pages = 303–309 |date=1994 | doi = 10.1016/0361-9230(94)90106-6| url = http://www.sciencedirect.com/science/article/pii/0361923094901066 | format = pdf }} 11. ^{{ cite journal |author1=Eikenburg, D. C. |author2=Stickney, J. L. | title = Anti-Cholinesterase Activity of 1-α-acetylmethadol: Relationship of Bradycardia | journal = General Pharmacology | volume = 10 | issue = 3 | pages = 195–200 |date=1979 | pmid = 467958 | doi = 10.1016/0306-3623(79)90089-2| url = http://ac.els-cdn.com/0306362379900892/1-s2.0-0306362379900892-main.pdf?_tid=5134dca0-826c-11e4-811d-00000aacb35e&acdnat=1418436425_32805186daf7f3e2c9bc794e1e5f6b9c | format = pdf }} 12. ^{{ cite journal |author1=Young, D. C. |author2=Vander Ploeg, A. |author3=Featherstone, R. M. |author4=Gross, E. G. | title = The Interrelationships Among the Central, Peripheral and Anticholinesterase Effects of Some Morphinan Derivatives | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 114 | issue = 2 | pages = 33–37 |date=May 1955 | pmid = 14392568 | doi = | url = http://jpet.aspetjournals.org/content/114/1/33.long | format = pdf }} 13. ^{{ cite journal |author1=Simantov, R. |author2=Snyder, S. H. | title = Opiate receptor binding in the pituitary gland| journal = Brain Research | volume = 124 | issue = 1 | pages = 178–184 |date= Dec 1976 | pmid = 191146 | doi = 10.1016/0006-8993(77)90877-0| url = http://www.sciencedirect.com/science/article/pii/0006899377908770 | format = pdf }} 4 : Alcohols|Morphinans|NMDA receptor antagonists|Sigma agonists |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。